GTDC2 modifies O-mannosylated α-dystroglycan in the endoplasmic reticulum to generate N-acetyl glucosamine epitopes reactive with CTD110.6 antibody

Biochemical and Biophysical Research Communications

Volumn 440, Issue 1, 2013, Pages 88-93

  Ogawa, Mitsutaka ^a,b   Nakamura, Naosuke ^c   Nakayama, Yoshiaki ^c   Kurosaka, Akira ^c   Manya, Hiroshi ^d   Kanagawa, Motoi ^e   Endo, Tamao ^d   Furukawa, Koichi ^a   Okajima, Tetsuya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^c KYOTO SANGYO UNIVERSITY   (Japan)

^d Tokyo Metropolitan Institute of Gerontology   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dystroglycan; CTD110.6; GTDC2; N Acetylglucosamine

Indexed keywords

ALANINE; ALPHA DYSTROGLYCAN; ANTIBODY; CTD110.6 ANTIBODY; EPITOPE; N ACETYLGLUCOSAMINE; N ACETYLGLUCOSAMINYLTRANSFERASE; O MANNOSYLATED ALPHA DYSTROGLYCAN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACYLATION; ALPHA DYSTROGLYCANOPATHY; AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GENE; GENE MUTATION; GLYCOSYLATION; GTDC2 GENE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MUSCULAR DYSTROPHY; PRIORITY JOURNAL; PROTEIN PURIFICATION; WALKER WARBURG SYNDROME;

Α-DYSTROGLYCAN; CTD110.6; DG; DYSTROGLYCAN; EGF; EGF DOMAIN O-GLCNAC TRANSFERASE; ENDOPLASMIC RETICULUM; EOGT; EPIDERMAL GROWTH FACTOR; ER; GLCNAC; GTDC2; N-ACETYLGLUCOSAMINE;

ACETYLGLUCOSAMINE; ANIMALS; ANTIBODIES; DYSTROGLYCANS; ENDOPLASMIC RETICULUM; EPITOPES; GLYCOSYLATION; GLYCOSYLTRANSFERASES; HEK293 CELLS; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY; WALKER-WARBURG SYNDROME;

EID: 84885381677     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.022     Document Type: Article

References (38)

1. Toda T., Kobayashi K., Takeda S., Sasaki J., Kurahashi H., Kano H., Tachikawa M., Wang F., Nagai Y., Taniguchi K., Taniguchi M., Sunada Y., Terashima T., Endo T., Matsumura K. Fukuyama-type congenital muscular dystrophy (FCMD) and α-dystroglycanopathy. Congenit. Anom. (Kyoto) 2003, 43:97-104.
2. Brockington M., Muntoni F. The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies. Acta Myol. 2005, 24:217-221.
3. Ervasti J.M., Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66:1121-1131.
4. Ervasti J.M., Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 1993, 122:809-823.
5. Ibraghimov-Beskrovnaya O., Ervasti J.M., Leveille C.J., Slaughter C.A., Sernett S.W., Campbell K.P. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992, 355:696-702.
6. Talts J.F., Andac Z., Göhring W., Brancaccio A., Timpl R. Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins. EMBO J. 1999, 18:863-870.
7. Durbeej M., Larsson E., Ibraghimov-Beskrovnaya O., Roberds S.L., Campbell K.P., Ekblom P. Non-muscle α-dystroglycan is involved in epithelial development. J. Cell Biol. 1995, 130:79-91.
8. Durbeej M., Henry M.D., Ferletta M., Campbell K.P., Ekblom P. Distribution of dystroglycan in normal adult mouse tissues. J. Histochem. Cytochem. 1998, 46:449-457.
9. Wright K.M., Lyon K.A., Leung H., Leahy D.J., Ma L., Ginty D.D. Dystroglycan organizes axon guidance cue localization and axonal pathfinding. Neuron 2012, 76:931-944.
10. Dobson C.M., Hempel S.J., Stalnaker S.H., Stuart R., Wells L. O-Mannosylation and human disease. Cell. Mol. Life Sci. 2012, 1-9.
11. Beltrán-Valero de Bernabé D., Currier S., Steinbrecher A., Celli J., van Beusekom E., van der Zwaag B., Kayserili H., Merlini L., Chitayat D., Dobyns W.B. Mutations in the O-Mannosyltransferase gene POMT1 give rise to the severe neuronal migration Disorder Walker-Warburg Syndrome. Am. J. Hum. Gen. 2002, 71:1033-1043.
12. van Reeuwijk J., Janssen M., van den Elzen C., de Bernabe D.B.-V., Sabatelli P., Merlini L., Boon M., Scheffer H., Brockington M., Muntoni F. POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 2005, 42:907-912.
13. Yoshida A., Kobayashi K., Manya H., Taniguchi K., Kano H., Mizuno M., Inazu T., Mitsuhashi H., Takahashi S., Takeuchi M. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 2001, 1:717-724.
14. Kobayashi K., Nakahori Y., Miyake M., Matsumura K., Kondo-Iida E., Nomura Y., Segawa M., Yoshioka M., Saito K., Osawa M. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394:388-392.
15. Brockington M., Blake D.J., Prandini P., Brown S.C., Torelli S., Benson M.A., Ponting C.P., Estournet B., Romero N.B., Mercuri E. Mutations in the Fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of α-dystroglycan. Am. J. Hum. Genet. 2001, 69:1198-1209.
16. Longman C., Brockington M., Torelli S., Jimenez-Mallebrera C., Kennedy C., Khalil N., Feng L., Saran R.K., Voit T., Merlini L. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan. Hum. Mol. Genet. 2003, 12:2853-2861.
17. Barone R., Aiello C., Race V., Morava E., Foulquier F., Riemersma M., Passarelli C., Concolino D., Carella M., Santorelli F. DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann. Neurol. 2012, 72:550-558.
18. Lefeber D.J., Schönberger J., Morava E., Guillard M., Huyben K.M., Verrijp K., Grafakou O., Evangeliou A., Preijers F.W., Manta P. Deficiency of dol-P-man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am. J. Hum. Genet. 2009, 85:76-86.
19. Lefeber D.J., de Brouwer A.P.M., Morava E., Riemersma M., Schuurs-Hoeijmakers J.H.M., Absmanner B., Verrijp K., van den Akker W.M.R., Huijben K., Steenbergen G. Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet. 2011, 7:e1002427.
20. Willer T., Lee H., Lommel M., Yoshida-Moriguchi T., de Bernabe D.B.V., Venzke D., Cirak S., Schachter H., Vajsar J., Voit T. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat. Genet. 2012, 44:575-580.
21. Cirak S., Foley A.R., Herrmann R., Willer T., Yau S., Stevens E., Torelli S., Brodd L., Kamynina A., Vondracek P. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain 2013, 136:269-281.
22. Roscioli T., Kamsteeg E.-J., Buysse K., Maystadt I., van Reeuwijk J., van den Elzen C., van Beusekom E., Riemersma M., Pfundt R., Vissers L.E.L.M. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of [alpha]-dystroglycan. Nat. Genet. 2012, 44:581-585.
23. Vuillaumier-Barrot S., Bouchet-Séraphin C., Chelbi M., Devisme L., Quentin S., Gazal S., Laquerrière A., Fallet-Bianco C., Loget P., Odent S. Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am. J. Hum. Genet. 2012, 91:1135-1143.
24. Manzini M.C., Tambunan D.E., Hill R.S., Yu T.W., Maynard T.M., Heinzen E.L., Shianna K.V., Stevens C.R., Partlow J.N., Barry B.J., Rodriguez J., Gupta V.A., Al-Qudah A.K., Eyaid W.M., Friedman J.M., Salih M.A., Clark R., Moroni I., Mora M., Beggs A.H., Gabriel S.B., Walsh C.A. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am. J. Hum. Genet. 2012, 91:541-547.
25. Stevens E., Carss K.J., Cirak S., Foley A.R., Torelli S., Willer T., Tambunan D.E., Yau S., Brodd L., Sewry C.A., Feng L., Haliloglu G., Orhan D., Dobyns W.B., Enns G.M., Manning M., Krause A., Salih M.A., Walsh C.A., Hurles M., Campbell K.P., Manzini M.C., Consortium U.K., Stemple D., Lin Y.Y., Muntoni F. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. Am. J. Hum. Genet. 2013, 92:354-365.
26. Buysse K., Riemersma M., Powell G., van Reeuwijk J., Chitayat D., Roscioli T., Kamsteeg E.J., van den Elzen C., van Beusekom E., Blaser S., Babul-Hirji R., Halliday W., Wright G.J., Stemple D.L., Lin Y.Y., Lefeber D.J., van Bokhoven H. Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum. Mol. Genet. 2013, 22:1746-1754.
27. Jae L.T., Raaben M., Riemersma M., van Beusekom E., Blomen V.A., Velds A., Kerkhoven R.M., Carette J.E., Topaloglu H., Meinecke P. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 2013, 340:479-483.
28. Wells L. The O-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy. J. Biol. Chem. 2013, 288:6930-6935.
29. Inamori K.-i., Yoshida-Moriguchi T., Hara Y., Anderson M.E., Yu L., Campbell K.P. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 2012, 335:93-96.
30. Sakaidani Y., Ichiyanagi N., Saito C., Nomura T., Ito M., Nishio Y., Nadano D., Matsuda T., Furukawa K., Okajima T. O-linked-N-acetylglucosamine modification of mammalian Notch receptors by an atypical O-GlcNAc transferase Eogt1. Biochem. Biophys. Res. Commun. 2012, 419:14-19.
31. Yoshida-Moriguchi T., Willer T., Anderson M.E., Venzke D., Whyte T., Muntoni F., Lee H., Nelson S.F., Yu L., Campbell K.P. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 2013, 341:896-899.
32. Hou X., Tashima Y., Stanley P. Galactose differentially modulates lunatic and manic fringe effects on Delta1-induced NOTCH signaling. J. Biol. Chem. 2012, 287:474-483.
33. Matsuura A., Ito M., Sakaidani Y., Kondo T., Murakami K., Furukawa K., Nadano D., Matsuda T., Okajima T. O-linked N-acetylglucosamine is present on the extracellular domain of notch receptors. J. Biol. Chem. 2008, 283:35486-35495.
34. Sakaidani Y., Nomura T., Matsuura A., Ito M., Suzuki E., Murakami K., Nadano D., Matsuda T., Furukawa K., Okajima T. O-linked-N-acetylglucosamine on extracellular protein domains mediates epithelial cell-matrix interactions. Nat. Commun. 2011, 2:583.
35. Isono T. O-GlcNAc-specific antibody CTD110. 6 cross-reacts with N-GlcNAc2-modified proteins induced under glucose deprivation. PLoS One 2011, 6:e18959.
36. Inamori K.-i., Endo T., Gu J., Matsuo I., Ito Y., Fujii S., Iwasaki H., Narimatsu H., Miyoshi E., Honke K. N-Acetylglucosaminyltransferase IX acts on the GlcNAcβ1, 2-Manα1-Ser/Thr moiety, forming α2,6-branched structure in brain O-mannosyl glycan. J. Biol. Chem. 2004, 279:2337-2340.
37. Harrison R., Hitchen P.G., Panico M., Morris H.R., Mekhaiel D., Pleass R.J., Dell A., Hewitt J.E., Haslam S.M. Glycoproteomic characterization of recombinant mouse α-dystroglycan. Glycobiology 2012, 22:662-675.
38. Hara Y., Kanagawa M., Kunz S., Yoshida-Moriguchi T., Satz J.S., Kobayashi Y.M., Zhu Z., Burden S.J., Oldstone M.B.A., Campbell K.P. Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection. Proc. Natl. Acad. Sci. 2011, 108:17426-17431.